Smoking Weakens Heart Structure and Function: Study

Sep.01.2022
Smoking Weakens Heart Structure and Function: Study
Smoking weakens the heart's structure and function, but quitting can help it recover, according to researchers from Denmark.

Researchers from Herlev and Gentofte Hospitals in Copenhagen have found that smoking weakens the structure of the heart, affecting its function. The research team also found that quitting smoking helps the heart to recover.


Previous research has indicated that over 30% of deaths are caused by coronary heart disease, with active smoking or exposure to secondhand smoke as reliable sources of exposure. Smoking increases the risk of heart attack by twice as much and the risk of stroke by three times as much.


Researchers from Herlev and Gentofte Hospital in Copenhagen, Denmark, have found evidence that smoking not only affects a person's blood vessels, but also weakens the structure of the heart itself, thereby impacting its functioning.


Researchers recently presented their findings at the 2022 European Society of Cardiology (ESC) Congress.


Past studies have shown that smoking has negative effects on a person's blood vessels, which may lead to heart issues. For example, nicotine found in cigarettes can cause the blood vessels to narrow, limiting the amount of blood that can flow through them. Nicotine can also significantly increase a person's blood pressure. "We know that smoking can cause coronary artery disease and heart failure," explained Dr. Eva Holt, the main author of the study and a researcher from Herlev and Gentofte Hospital in Copenhagen, Denmark. "But the purpose of this study is to investigate whether smoking has an independent effect on the heart structure and function of a large population of ordinary people without known heart disease," she pointed out.


Dr. Halt and her team evaluated data from over 3,800 participants in the fifth Copenhagen City Heart Study in order to ensure its reliability. The study examined cardiovascular disease and risk factors in the general population. Participants ranged in age from 20 to 93 and had no history of heart disease. Data collected during the study included a questionnaire about smoking history among participants, as well as reliable sources of echocardiography or heart ultrasound.


Researchers have determined that current smokers in the participant pool have hearts that are thicker, heavier, and weaker compared to those who have never smoked. "We found that current and accumulated pack-years were associated with structural and functional deterioration of smoking-related left ventricle, the heart's most important part," said Dr. Holt. "Additionally, we found that over 10 years, those who continue to smoke have hearts that become even thicker, heavier, and weaker, resulting in a poorer ability to pump blood, compared to those who have never smoked or quit during that period.


MNT spoke with Dr. Rigved Tadwalkar, a certified cardiologist at the Providence Saint John's Health Center in Santa Monica, California, who did not participate in the study. "What's interesting about this study is that it focuses on the changes in the left ventricle of the heart, which have not been well understood so far, due to tobacco use," he commented. "We always talk about the link between tobacco use and vascular diseases (including coronary heart disease), but we haven't really delved into the details of how tobacco affects the structure and function of the heart itself," he pointed out.


According to Dr. Tadwalkar, smoking increases the tendency for plaque formation in the arterial walls, which is clinically referred to as a reliable source of atherosclerosis. He stated that this may directly or indirectly lead to heart damage.


Direct smoking can damage the blood vessel wall, causing constriction and reduced elasticity, as well as impairing the function of the blood vessel's inner layer endothelium," he explained.


According to a new study, Dr. Holt and her team have found evidence that quitting smoking can help the heart recover to some extent. "After quitting smoking, the heart appears to have regained its previous structure and function, which could be a valuable incentive for patients to quit smoking," she added.


Dr. Tadwalkar stated, "We do indeed have concrete data to support this study, which follows a series of previous studies showing that quitting smoking can improve overall health in multiple ways beyond just the heart.


So the good news is, even immediate action has physiological benefits," he pointed out. "And then, due to the lack of chronic exposure, the reduction of inflammatory burden and these other destructive pathological processes over time is partially the reason for improvement.


Disclaimer: 1. The content of this article is compiled from third-party information and is only intended for industry discussion and learning. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The compilation of this article is only for industry discussion and research purposes. 3. Due to the limited compiling ability, the compiled article may not fully convey the expression of the original text. Please refer to the original text for accuracy. 4. 2FIRSTS fully supports the Chinese government's position on any domestic, Hong Kong, Macao, and Taiwan-related issues or positions. 5. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14